- Co-investors aim to invest over £10m in early stage Scottish life sciences ventures over next 5 years
- North Carolina HQ-ed Kineticos Life Sciences manages Kineticos Disruptor Fund
- Partnership will seek out investment opportunities that address unmet needs in oncology, with new approaches to advanced cell and gene therapies, and precision medicine technologies
- Eos Chairman Kevin Grainger says this partnership will “provide significant new funding for the best of Scotland’s oncology life sciences technologies, creating high value R&D jobs in Scotland and commercial opportunities in the US”
- Kineticos CEO Shailesh Maingi says “Our core mission is to advance life science research by supporting biotech companies in their pursuit of new treatments for patients and Scotland presents a unique opportunity with its rich history in life sciences innovation and entrepreneurial culture”
ST Andrews, Scotland and Raleigh, North Carolina, 15 February 2021 – St Andrews-based investment firm Eos Advisory has entered into a strategic partnership with US-based Kineticos Life Sciences to co-invest in early-stage Scottish life sciences companies. The venture partnership aims to invest over £10 million over the next five years in oncology-focused life sciences ventures founded in Scotland. Headquartered in Raleigh, North Carolina, Kineticos has a biotech advisory practice and a related fund, the Kineticos Disruptor Fund, to invest in the advancement and commercialisation of clinical research.
As part of the deal, Eos will engage with Scottish Enterprise and a range of other private and public investors to leverage its co-investments. Specifically, the partnership will seek out Scottish-based investment opportunities that address large, unmet medical needs in oncology, neurosciences and rare diseases, new approaches to gene and cell therapies, and precision medicine technologies.
Kevin Grainger, Founder and Chairman of Eos Advisory, said: “This strategic transatlantic partnership between Eos and Kineticos will help find and fund breakthrough ideas from Scotland’s brightest life science entrepreneurs. In addition to the £10m Eos and Kineticos have committed, we will leverage additional equity capital from private, institutional and public sources to maximise the impact of these nascent oncology businesses. This funding, along with the commercial expertise of the Eos and Kineticos teams, will accelerate high skill R&D job creation in Scotland and subsequent commercial opportunities in the US which we hope will have a significant impact on improving the early diagnosis and treatment of cancer globally.”
Shailesh Maingi, Founder and Chairman of Kineticos, said: “The Kineticos Disruptor Fund’s mission is simple: to find cures for difficult to treat cancers and rare diseases. The fund invests in cutting edge technology such as Cell and Gene Therapy (CGT), emanating from the world’s leading research scientists and universities. Scotland presents a unique opportunity with its rich history in life sciences innovation and entrepreneurial culture. With our partnership with the excellent Eos team, we hope to build upon the success of Scotland’s ecosystem and create a new path for collaboration between leading scientists in Scotland and the United States.”
Mark Bamforth, an investor in the Kineticos Disruptor Fund, said “As a Scot, I am delighted to support this partnership which will help to fund and mentor Scottish companies to support their development and global growth.”